Thiazolidinediones Another area of investigation concerns the role of the thiazolidinediones in CVD prevention. Rosigli­tazone, a peroxisome proliferator-activated receptor (PPAR)-g agonist that is used in the treatment of type-2 diabetes, is also known to have anti-inflammatory effects. In 84 patients with stable, angio-graphically documented CAD and no diabetes who were randomized to rosiglitazone or placebo [...]

Statin Therapy for Elevated CRP In the last two decades, many randomized controlled trials of statin therapy have demonstrated that these agents reduce the risk of myocardial infarction (MI), stroke and other cardiovascular events in patients with known CVD and those at high risk. We also know that statins have a favorable effect on the [...]

Metabolic Syndrome, CRP and Cardiovascular Events The impact of metabolic syndrome on mortality from coronary heart disease (CHD) or CVD was examined in a prospective cohort of 6,255 subjects representative of the U.S. adult population at large and who were followed for a mean of 13.3 years. Although the presence of diabetes predicted all mortality [...]

CRP and Metabolic Dysfunction in Nonwhite Populations Type-2 diabetes is more common in African Americans than in whites, probably due to both genetic and environmental risk factors. Moreover, African Americans have a higher risk of the microvascular complications of diabetes than do whites, possibly due to a higher prevalence of preexisting high blood pressure. Whereas [...]

CRP and Metabolic Dysfunction In 1988, Reaven proposed that insulin resistance is causally linked to hypertension and associated with atherogenic dyslipidemia [elevated triglycerides, decreased high-density lipoprotein cholesterol (HDL-C) and small LDL particles] and impaired glucose tolerance. These conditions are diagnostic criteria for a cluster of lipid and metabolic abnormalities formerly called the insulin resistance syndrome [...]

The incidence of obesity is increasing in the American population. This inarguable fact is a cause of concern for politicians and industrial leaders, whose firms carry the cost of healthcare, as well as for physicians, who will be increasingly burdened with the long-term health consequences of this demographic trend. The public health implications of the [...]